FHTX on Nasdaq
Foghorn Therapeutics Inc.
American pharmaceutical preparations company, incorporated in Delaware. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Verastem Oncology, Zomedica Corp. or Arcus Biosciences, or pick any stock.
- TickerFHTX on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersCambridge, Massachusetts1
- Incorporated inDE2
- Business address500 Technology Square, Suite 700, Cambridge, Ma 021392
- Filer categoryNon-accelerated filer, Smaller reporting company2
See how the biggest companies compare on our leaderboards
Foghorn is a clinical stage, precision therapeutics biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system, an untapped opportunity for therapeutic intervention in oncology and with potential in a wide spectrum of other diseases, including immunology and inflammation.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$85.5M
Out of $30.9M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Collaboration revenue | $30.9M | $22.6M |
| Research and development | $85.5M | $94.5M |
| General and administrative | $27.6M | $28.4M |
| Gain on lease modification | -$1.6M | $0 |
| Impairment of long-lived assets | $5.9M | $2.4M |
| Total operating expenses | $117.3M | $125.3M |
| Loss from operations | -$86.4M | -$102.7M |
| Interest income | $8.7M | $11.9M |
| Other income, net | $3.4M | $4.2M |
| Total other income, net | $12.1M | $16.1M |
| Net loss per share attributable to common stockholdersbasic (in dollars per share) | -$1.18 | -$1.58 |
| Net loss per share attributable to common stockholdersdiluted (in dollars per share) | -$1.18 | -$1.58 |
| Weighted average common shares outstandingbasic (in shares) | 63.0M shares | 54.9M shares |
| Weighted average common shares outstandingdiluted (in shares) | 63.0M shares | 54.9M shares |
| Net loss | -$74.3M | -$86.6M |
| Unrealized gains (losses) on marketable securities | -$111.0K | $961.0K |
| Total other comprehensive gain (loss) | -$111.0K | $961.0K |
| Total comprehensive loss | -$74.4M | -$85.7M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $80.9M | $55.5M | |
| Marketable securities | $78.0M | $188.3M | |
| Restricted cash | $1.2M | $0 | |
| Prepaid expenses and other current assets | $3.1M | $5.9M | |
| Total current assets | $163.2M | $249.6M | |
| Property and equipment, net | $1.9M | $10.0M | |
| Restricted cash | $2.0M | $1.7M | |
| Other assets | $4.0K | $68.0K | |
| Operating lease right-of-use assets | $30.9M | $22.6M | |
| Total assets | $198.1M | $284.0M | |
| Accounts payable | $4.3M | $3.8M | |
| Accrued expenses and other current liabilities | $11.4M | $8.5M | |
| Operating lease liabilities | $923.0K | $9.1M | |
| Deferred revenue | $43.2M | $45.6M | |
| Total current liabilities | $59.7M | $67.0M | |
| Operating lease liabilities, net of current portion | $40.3M | $28.1M | |
| Deferred revenue, net of current portion | $206.0M | $234.5M | |
| Other liabilities | $556.0K | $0 | |
| Total liabilities | $306.6M | $329.5M | |
| Preferred stock, $0.0001 par value; 25,000,000 shares authorized as of December 31, 2025 and 2024; no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | |
| Common stock, $0.0001 par value; 175,000,000 shares authorized at December 31, 2025 and 2024; 56,657,329 shares issued and outstanding at December 31, 2025 and 55,594,131 shares issued and outstanding at December 31, 2024 | $6.0K | $6.0K | |
| Additional paid-in capital | $523.9M | $512.5M | |
| Accumulated other comprehensive gain | $24.0K | $135.0K | |
| Accumulated deficit | -$632.5M | -$558.2M | |
| Total stockholders deficit | -$108.5M | -$45.5M | -$77.2M |
| Total liabilities and stockholders deficit | $198.1M | $284.0M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock authorized (in shares) | 25.0M shares | 25.0M shares | |
| Preferred stock, shares, issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares, outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 175.0M shares | 175.0M shares | |
| Common stock, shares, issued (in shares) | 56.7M shares | 55.6M shares | |
| Common stock, shares, outstanding (in shares) | 56.7M shares | 55.6M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $80.9M | $55.5M | |
| Marketable securities | $78.0M | $188.3M | |
| Restricted cash | $1.2M | $0 | |
| Prepaid expenses and other current assets | $3.1M | $5.9M | |
| Total current assets | $163.2M | $249.6M | |
| Property and equipment, net | $1.9M | $10.0M | |
| Restricted cash | $2.0M | $1.7M | |
| Other assets | $4.0K | $68.0K | |
| Operating lease right-of-use assets | $30.9M | $22.6M | |
| Total assets | $198.1M | $284.0M | |
| Accounts payable | $4.3M | $3.8M | |
| Accrued expenses and other current liabilities | $11.4M | $8.5M | |
| Operating lease liabilities | $923.0K | $9.1M | |
| Deferred revenue | $43.2M | $45.6M | |
| Total current liabilities | $59.7M | $67.0M | |
| Operating lease liabilities, net of current portion | $40.3M | $28.1M | |
| Deferred revenue, net of current portion | $206.0M | $234.5M | |
| Other liabilities | $556.0K | $0 | |
| Total liabilities | $306.6M | $329.5M | |
| Preferred stock, $0.0001 par value; 25,000,000 shares authorized as of December 31, 2025 and 2024; no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | |
| Common stock, $0.0001 par value; 175,000,000 shares authorized at December 31, 2025 and 2024; 56,657,329 shares issued and outstanding at December 31, 2025 and 55,594,131 shares issued and outstanding at December 31, 2024 | $6.0K | $6.0K | |
| Additional paid-in capital | $523.9M | $512.5M | |
| Accumulated other comprehensive gain | $24.0K | $135.0K | |
| Accumulated deficit | -$632.5M | -$558.2M | |
| Total stockholders deficit | -$108.5M | -$45.5M | -$77.2M |
| Total liabilities and stockholders deficit | $198.1M | $284.0M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock authorized (in shares) | 25.0M shares | 25.0M shares | |
| Preferred stock, shares, issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares, outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 175.0M shares | 175.0M shares | |
| Common stock, shares, issued (in shares) | 56.7M shares | 55.6M shares | |
| Common stock, shares, outstanding (in shares) | 56.7M shares | 55.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$74.3M | -$86.6M |
| Stock-based compensation expense | $10.4M | $11.9M |
| Depreciation and amortization expense | $3.3M | $3.1M |
| Loss on disposal of property and equipment | $31.0K | $0 |
| Gain on lease modification | -$1.6M | $0 |
| Impairment of long-lived assets | $5.9M | $2.4M |
| Noncash lease expense | $4.2M | $5.7M |
| Accretion of discount on marketable securities | -$1.9M | -$4.6M |
| Prepaid expenses and other current assets | $2.8M | $1.3M |
| Accounts payable | $481.0K | -$2.5M |
| Accrued expenses and other liabilities | $2.2M | -$564.0K |
| Operating lease liabilities | -$6.7M | -$7.9M |
| Deferred revenue | -$30.9M | -$22.6M |
| Net cash used in operating activities | -$86.1M | -$100.4M |
| Purchases of property and equipment | -$50.0K | -$906.0K |
| Purchases of marketable securities | -$131.2M | -$261.5M |
| Proceeds from maturities of marketable securities | $243.3M | $232.5M |
| Net cash provided by (used in) investing activities | $112.0M | -$29.9M |
| Payments of public offering costs | $0 | -$585.0K |
| Proceeds from issuance of common stock upon exercise of stock options and employee stock purchase plan | $483.0K | $2.6M |
| Net cash provided by financing activities | $1.0M | $105.4M |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $27.0M | -$24.9M |
| Cash paid for taxes | $9.0K | $860.0K |
| Purchases of property and equipment included in accounts payable and accrued expenses | $0 | $22.0K |
| Asset acquired in finance lease | $1.2M | $0 |
No quarter-by-quarter statement was filed.
Leadership
Who has led Foghorn Therapeutics Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
2025
- Chief executive officerAdrian Gottschalk Aug 23, 2021 to now12
- Chief financial officerRyan D. Maynard Feb 24, 2026 to now13
- Chief financial officerKristian Humer Apr 17, 2024 to Feb 24, 202614
- Chief financial officerAllan Reine Oct 22, 2020 to Jan 17, 202415
Board members and other officers (22)
- Chief Business OfficerAnna Rivkin Sep 4, 2024 to now16
- Chief Medical OfficerAlfonso Quintas Cardama Sep 13, 2023 to now17
- Chief Strategy/Bus Ops OfficerFanny Cavalie Feb 24, 2022 to Jun 24, 202418
- Chief People OfficerCarlos Costa Aug 3, 2022 to now19
- OfficerAdrian Gottschalk Oct 22, 2020 to Feb 1, 202120
- Chief Scientific OfficerCarl Decicco Oct 22, 2020 to Dec 13, 202121
- Chief Medical OfficerSamuel Agresta Oct 22, 2020 to Sep 13, 202322
- OfficerSteven F. Bellon Nov 13, 2020 to now23
- Board memberNoubar Afeyan Jan 15, 2026 to now24
- Board memberNeil Gallagher May 2, 2025 to now25
- Board memberStuart Duty May 2, 2025 to now26
- Board memberB. Lynne Parshall Aug 18, 2022 to now27
- Board memberIan F. Smith Apr 29, 2021 to now28
- Board memberAdam Koppel Oct 22, 2020 to now29
- Board memberAdrian Gottschalk Oct 22, 2020 to now20
- Board memberCigall Kadoch Oct 22, 2020 to Sep 2, 202230
- Board memberDouglas G. Cole Oct 22, 2020 to now31
- Board memberJose Baselga Oct 22, 2020 to Oct 22, 202032
- Board memberMichael Mendelsohn Oct 22, 2020 to now33
- Board memberScott Biller Oct 22, 2020 to now34
- Board memberSimba Gill Oct 22, 2020 to now35
- General counselMichael Lacascia Nov 13, 2020 to now36
Timeline
- Aug 23, 2021New chief executive Adrian Gottschalk becomes CEO12
Filings
274 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 75 major events, 123 insider forms, 14 large holders, 40 other. The latest 20:
- Oct 5, 20263 OWNERSHIP DOCUMENT EDGAR
- Oct 5, 2026SCHEDULE 13G/A EDGAR
- Oct 1, 20268-K EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Jun 25, 20264 PRIMARY DOCUMENT EDGAR
- Jun 25, 20264 PRIMARY DOCUMENT EDGAR
- Jun 25, 20264 PRIMARY DOCUMENT EDGAR
- Jun 25, 20264 PRIMARY DOCUMENT EDGAR
- Jun 25, 20264 PRIMARY DOCUMENT EDGAR
- Jun 25, 20264 PRIMARY DOCUMENT EDGAR
- Jun 25, 20264 PRIMARY DOCUMENT EDGAR
- Jun 25, 20264 PRIMARY DOCUMENT EDGAR
- Jun 25, 20264 PRIMARY DOCUMENT EDGAR
- Jun 24, 20268-K EDGAR
- May 15, 2026SCHEDULE 13G/A EDGAR
- May 14, 2026SCHEDULE 13G/A EDGAR
- May 7, 202610-Q EDGAR
- May 7, 20268-K EDGAR
- May 6, 2026SCHEDULE 13G/A EDGAR
The 274 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
8 open-market trades by officers, directors and large owners since October 2021: 0 buys and 8 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 23, 2024 | Costa CarlosChief People Officer | Sale | 857 | $10.17 | $8.7K | Form 4 |
| Sep 20, 2024 | Costa CarlosChief People Officer | Sale | 35,756 | $10.04 | $359.0K | Form 4 |
| Sep 18, 2024 | Costa CarlosChief People Officer | Sale | 11,574 | $10.05 | $116.3K | Form 4 |
| Sep 17, 2024 | Costa CarlosChief People Officer | Sale | 10,272 | $10.04 | $103.1K | Form 4 |
| Sep 16, 2024 | Costa CarlosChief People Officer | Sale | 400 | $10.00 | $4.0K | Form 4 |
| Sep 9, 2024 | Bellon Steven F.Chief Scientific Officer | Sale | 20,000 | $9.50 | $190.0K | Form 4 |
| Mar 11, 2024 | Cavalie FannyChief Strategy/Bus Ops Officer | Sale | 11,000 | $6.56 | $72.2K | Form 4 |
| Aug 16, 2023 | Agresta SamuelChief Medical Officer | Sale | 311,297 | $8.25 | $2.6M | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- BIOTECHNOLOGY VALUE FUND L PSCHEDULE 13G/A, 3 filings May 30, 2024 to Oct 5, 202637
- James E. FlynnSCHEDULE 13G/A, 2 filings Sep 20, 2024 to May 14, 202638
- FMR LLCSCHEDULE 13G/A, 6 filings Feb 9, 2022 to May 6, 202639
- Flagship Ventures Fund V, L.P.SCHEDULE 13D/A, 2 filings May 24, 2024 to Jan 13, 202640
- Klarman Family FoundationSC 13G/A, 1 filing Oct 8, 202441
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Flagship Pioneering, LLC | 12,674,120 | $61.8M | 4.0% | No change |
| Bvf Inc/il | 5,842,000 | $28.5M | 0.7% | No change |
| Fmr LLC | 5,705,958 | $27.8M | 0.0% | −341,240 |
| Deerfield Management Company, L.P. | 4,394,367 | $21.4M | 0.3% | No change |
| BlackRock, Inc. | 2,626,832 | $12.8M | 0.0% | +261,966 |
| Raymond James Financial Inc | 2,489,978 | $12.2M | 0.0% | −112,404 |
| Euclidean Capital LLC | 1,573,761 | $7.7M | 1.7% | No change |
| Vanguard Capital Management LLC | 1,494,611 | $7.3M | 0.0% | −478 |
| Geode Capital Management, LLC | 910,866 | $4.4M | 0.0% | +62,694 |
| Siren, L.L.C. | 720,720 | $3.5M | 0.1% | No change |
| State Street Corp | 697,469 | $3.4M | 0.0% | +17,682 |
| Ameriprise Financial Inc | 558,685 | $2.7M | 0.0% | +109,709 |
| Renaissance Technologies LLC | 377,936 | $1.8M | 0.0% | −28,489 |
| Candriam S.C.A. | 313,765 | $1.5M | 0.0% | No change |
| Northern Trust Corp | 309,775 | $1.5M | 0.0% | +33,900 |
| Jacobs Levy Equity Management, Inc | 305,434 | $1.5M | 0.0% | +1,677 |
| Vanguard Portfolio Management LLC | 304,432 | $1.5M | 0.0% | +48,501 |
| Birchview Capital, LP | 281,937 | $1.4M | 0.6% | +207 |
| Vanguard Fiduciary Trust Co | 264,422 | $1.3M | 0.0% | +23,836 |
| Qube Research & Technologies Ltd | 203,296 | $992.1K | 0.0% | +122,018 |
| Woodline Partners LP | 202,145 | $986.5K | 0.0% | +21,812 |
| B Group, Inc. | 200,000 | $976.0K | 0.6% | +98,000 |
| Panagora Asset Management Inc | 175,406 | $856.0K | 0.0% | +60,343 |
| Goldman Sachs Group Inc | 164,256 | $801.6K | 0.0% | +28,148 |
| Citadel Advisors LLC | 158,822 | $775.1K | 0.0% | −41,191 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15SEC EDGARAllan Reine, Chief financial officer
- 16SEC EDGARAnna Rivkin, Chief Business Officer
- 17
- 18
- 19SEC EDGARCarlos Costa, Chief People Officer
- 20SEC EDGARAdrian Gottschalk, Officer
- 21
- 22
- 23SEC EDGARSteven F. Bellon, Officer
- 24SEC EDGARNoubar Afeyan, Board member
- 25SEC EDGARNeil Gallagher, Board member
- 26SEC EDGARStuart Duty, Board member
- 27SEC EDGARB. Lynne Parshall, Board member
- 28SEC EDGARIan F. Smith, Board member
- 29SEC EDGARAdam Koppel, Board member
- 30SEC EDGARCigall Kadoch, Board member
- 31SEC EDGARDouglas G. Cole, Board member
- 32SEC EDGARJose Baselga, Board member
- 33SEC EDGARMichael Mendelsohn, Board member
- 34SEC EDGARScott Biller, Board member
- 35SEC EDGARSimba Gill, Board member
- 36SEC EDGARMichael Lacascia, General counsel
- 37
- 38
- 39
- 40
- 41